Blair William & Co. IL Purchases 36,335 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Blair William & Co. IL lifted its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 49.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 109,401 shares of the biotechnology company’s stock after purchasing an additional 36,335 shares during the period. Blair William & Co. IL owned 0.15% of Viking Therapeutics worth $637,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. American International Group Inc. increased its holdings in shares of Viking Therapeutics by 4.4% during the 2nd quarter. American International Group Inc. now owns 40,099 shares of the biotechnology company’s stock worth $289,000 after acquiring an additional 1,684 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of Viking Therapeutics by 3.7% in the first quarter. Royal Bank of Canada now owns 47,655 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 1,693 shares during the last quarter. Brinker Capital Inc. increased its holdings in shares of Viking Therapeutics by 6.1% in the second quarter. Brinker Capital Inc. now owns 31,712 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 1,811 shares during the last quarter. Wedbush Securities Inc. raised its position in shares of Viking Therapeutics by 13.2% in the third quarter. Wedbush Securities Inc. now owns 21,500 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 2,500 shares during the period. Finally, Macquarie Group Ltd. lifted its stake in shares of Viking Therapeutics by 0.8% during the 2nd quarter. Macquarie Group Ltd. now owns 332,645 shares of the biotechnology company’s stock worth $2,398,000 after buying an additional 2,545 shares during the last quarter. 55.30% of the stock is currently owned by institutional investors.

Shares of Viking Therapeutics stock opened at $6.31 on Friday. The business has a 50-day simple moving average of $5.89 and a 200 day simple moving average of $6.74. Viking Therapeutics, Inc. has a one year low of $3.26 and a one year high of $8.87. The firm has a market capitalization of $460.33 million, a price-to-earnings ratio of -14.34 and a beta of 2.02.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. On average, sell-side analysts predict that Viking Therapeutics, Inc. will post -0.61 earnings per share for the current fiscal year.

VKTX has been the topic of a number of research reports. Oppenheimer restated a “buy” rating and set a $12.00 price objective on shares of Viking Therapeutics in a research report on Wednesday, July 29th. Raymond James increased their price objective on shares of Viking Therapeutics from $25.00 to $27.00 and gave the stock a “strong-buy” rating in a research report on Thursday, October 29th. Chardan Capital lifted their target price on shares of Viking Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, August 31st. BidaskClub raised shares of Viking Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 6th. Finally, William Blair reiterated a “buy” rating on shares of Viking Therapeutics in a report on Friday, September 11th. One research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Viking Therapeutics presently has an average rating of “Buy” and an average price target of $16.56.

In other Viking Therapeutics news, major shareholder Ligand Pharmaceuticals Inc sold 164,488 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $8.07, for a total transaction of $1,327,418.16. Company insiders own 3.70% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis.

See Also: Hedge Funds – Risk or Reward?

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.